Sheaff Brock Investment Advisors LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,950 shares of the company’s stock after selling 1,567 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Eli Lilly and were worth $2,712,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of the stock. Heritage Trust Co purchased a new position in Eli Lilly and in the first quarter worth about $135,000. Point72 Asia Hong Kong Ltd raised its holdings in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares during the last quarter. Shine Investment Advisory Services Inc. purchased a new position in Eli Lilly and in the second quarter worth about $148,000. Cornerstone Advisors Inc. raised its holdings in Eli Lilly and by 18.4% in the second quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock worth $166,000 after buying an additional 313 shares during the last quarter. Finally, Penserra Capital Management LLC raised its holdings in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the last quarter. 75.66% of the stock is currently owned by institutional investors and hedge funds.
Shares of Eli Lilly and Company (LLY) opened at 81.94 on Wednesday. The company has a market capitalization of $86.45 billion, a price-to-earnings ratio of 35.46 and a beta of 0.34. The company’s 50-day moving average is $84.88 and its 200 day moving average is $82.19. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.72%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.88 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post $4.21 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.54%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.
Several brokerages have issued reports on LLY. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the stock a “hold” rating in a report on Friday, October 6th. Leerink Swann lifted their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, October 24th. Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and boosted their price objective for the company from $84.23 to $88.00 in a report on Tuesday, October 10th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $95.00 price objective (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. Eli Lilly and has a consensus rating of “Hold” and an average target price of $89.76.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.com-unik.info/2017/11/01/sheaff-brock-investment-advisors-llc-reduces-position-in-eli-lilly-and-company-lly.html.
In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 770,000 shares of company stock valued at $64,669,850. Insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.